Sickle cell disease

Hemoglobin carries oxygen inside red blood cells. Sickle hemoglobin can form long polymers when oxygen is low, making cells less flexible. Red-cell injury, inflammation and impaired small-vessel blood flow all contribute to disease.

Sickle cell disease includes HbSS, HbSC, sickle beta-thalassemia and other combinations. Sickle cell trait is different. The genotype matters, but people with the same genotype can still have very different symptoms.

The condition involves inherited HBB variants, including at least one sickle hemoglobin variant. Family testing and genetic counseling can explain the specific combination and reproductive implications.

It occurs in people from many ancestries around the world. It is not defined by race, and it cannot be caught from another person.

Shortened red-cell survival causes anemia and jaundice. Reduced blood flow can cause acute pain episodes and contribute to chronic pain. The brain, lungs, kidneys, eyes, bones and other organs can be affected.

Complications include stroke, serious infection and acute chest syndrome, a potentially dangerous lung illness. New chest pain, breathing difficulty, fever or stroke-like symptoms require prompt medical assessment using the person’s emergency plan.

Care includes vaccination, infection prevention, pain treatment and monitoring for organ complications. Hydroxyurea increases fetal hemoglobin and can reduce important complications. Transfusions are used for selected indications such as stroke prevention or severe acute illness; repeated transfusions may require iron management.

An allogeneic transplant uses another person’s blood-forming cells. Matched sibling transplantation has a long evidence base, and unrelated or partially matched family donors may be considered with appropriate protocols. Suitability depends on disease burden, organ health, age, donor options and center experience.

In the United States, Casgevy uses gene editing to increase fetal hemoglobin, while Lyfgenia adds a modified beta-globin gene. Both use the patient’s own stem cells and have specific eligibility criteria. They do not require a registry donor.

Gene therapy still requires stem-cell collection, conditioning chemotherapy and long-term follow-up. Risks include infertility and treatment toxicity; Lyfgenia carries a boxed warning for hematologic malignancy. Neither gene therapy nor donor transplant guarantees reversal of established organ injury.

A care plan may include daily medicines, screening, transfusions and support for pain or fatigue. People can need help with education, employment, mental health and the transition from pediatric to adult services.

Availability differs between countries and health systems. Cost, referral, blood supply, specialist capacity and long-term follow-up can shape access to both routine and intensive treatment. A person’s options cannot be inferred from a national approval alone.

An unrelated donor may be part of a specialist transplant plan, but family donors and autologous gene therapies are also important pathways. No single donor route applies to everyone with sickle cell disease.

HLA compatibility and donor suitability guide a search. Broader registry representation can expand options for patients needing unrelated transplantation. Access to specialist care, treatment and long-term follow-up also matters. Gene therapy uses the patient’s own cells.

What is the exact diagnosis or subtype? What is the goal of each treatment option? If transplant is being considered, why does it fit this situation, which cells would be used and what are the alternatives?